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ABSTRACT
Apoptosis caused by deregulated MYC expression is a prototype example of intrinsic tumor suppression.
However, it is still unclear how supraphysiological MYC expression levels engage speciﬁc sets of target
genes to promote apoptosis. Recently, we demonstrated that repression of SRF target genes by MYC/MIZ1
complexes limits AKT-dependent survival signaling and contributes to apoptosis induction. Here we report
that supraphysiological levels of MYC repress gene sets that include markers of basal-like breast cancer
cells, but not luminal cancer cells, in a MIZ1-dependent manner. Furthermore, repressed genes are part of
a conserved gene signature characterizing the basal subpopulation of both murine and human mammary
gland. These repressed genes play a role in epithelium and mammary gland development and overlap
with genes mediating cell adhesion and extracellular matrix organization. Strikingly, acute activation of
oncogenic MYC in basal mammary epithelial cells is sufﬁcient to induce luminal cell identity markers. We
propose that supraphysiological MYC expression impacts on mammary epithelial cell identity by
repressing lineage-speciﬁc target genes. Such abrupt cell identity switch could interfere with adhesion-
dependent survival signaling and thus promote apoptosis in pre-malignant epithelial tissue.
KEYWORDS
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Introduction
Deregulated MYC expression is pervasive in multiple human
tumor entities and is one of the ﬁrst genetic alterations identi-
ﬁed in human breast cancer.1
In a heterodimeric complex with MAX, MYC proteins bind
E-boxes (50-CANNTG-30) in promoters to control gene expres-
sion and exert most of their biological functions, including
growth control, cell cycle progression and differentiation.2 In
some biological contexts, such as the mitogenic stimulation of
resting B-cells, MYC enhances expression of all genes with an
open chromatin structure.3-5 In contrast, deregulation of MYC
activates and represses more restricted sets of target genes dur-
ing tumorigenesis.6 For example, complex formation with MIZ1
(ZBTB17), which occurs predominantly at oncogenic MYC lev-
els, mediates binding to low-afﬁnity sites and shifts the direction
of transcriptional responses at these “newly acquired” target
genes toward repression.6,7 In addition, high levels of MYC can
regulate genes by binding to distal enhancer elements.8
In addition to promoting cell growth and transformation,
deregulated expression of MYC sensitizes cells to apoptosis in
multiple settings.9-11 Consistently, impairment of apoptosis is a
central feature during tumor progression and mutation or loss
of apoptotic regulators accelerates MYC-induced tumorigenesis
in different tissues in vivo.12-14
For example, mice expressing Myc under the control of
either the whey acidic protein (WAP) or the mouse mammary
tumor virus (MMTV) promoters develop mammary adenocar-
cinomas after long latencies, indicating that deregulation of Myc
alone is insufﬁcient to promote transformation in mammary
epithelial cells without additional genetic lesions.15-17 In these
models, Myc-dependent mammary tumorigenesis is most likely
limited by the induction of apoptosis, since tumors display
increased levels of apoptosis and overexpression of Bcl-2 in the
MMTV-Myc background accelerates tumor development.18,19
Although several molecular factors involved in MYC-
induced apoptosis have been identiﬁed, the mechanisms that
enable cells to react to different levels of the transcription factor
with the appropriate biological response had remained elusive.
We have previously reported that MCF10A mammary epithe-
lial cells engineered to express high levels of the 4-OHT induc-
ible fusion protein MYC-ER undergo apoptosis. Importantly, a
mutant form of MYC, MYCVD-ER, which is unable to bind to
MIZ1, displays a strongly impaired response.7 Detailed analyses
of MIZ1-dependent gene expression changes revealed that
dose-dependent apoptosis induction by MYC correlated with
repression of target genes of the serum response factor (SRF)
and reduced AKT activity.7 These observations expand several
other studies that had demonstrated a correlation between
MYC-mediated transcriptional repression and the induction of
apoptosis.20,21
Collectively, the available data suggest that oncogenic
amounts of MYC, due to association with MIZ1 at these levels,
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Figure 1. (For ﬁgure legend, see next page.)
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lead to repression of genes that normally provide critical sur-
vival signals. Here, we aimed to gain more insight into the
identity of these target genes and their signiﬁcance for apopto-
sis induction in response to high levels of MYC.
Results
To elucidate how MIZ1-dependent repression contributes to
MYC-induced apoptosis, we performed a gene set enrichment
analysis (GSEA) using microarray expression data obtained
from MCF10A cells expressing MYC-ER. We directly com-
pared gene expression changes induced by 4-OHT-activated
MYC-ER or the MYCVD-ER mutant form of MYC that cannot
bind MIZ1.
MCF10As are non-tumorigenic mammary epithelial cells
displaying a gene expression program characteristic of normal
basal epithelial cells.22 Interestingly, the most prominently
repressed gene set in response to MYC-ER was composed of
genes that are upregulated in basal-like breast cancer cell lines
relative to luminal cells (Fig. 1A). In addition, 3 other gene sets
comparing basal- with luminal-speciﬁc gene expression pat-
terns in tumor cell lines as well as normal mammary epithelial
cells were identiﬁed with a false discovery rate of 0.000.
(Fig. 1A).23-25
To validate repression of basal marker genes by MYC, we
isolated RNA from pools of MYC-ER and MYCVD-ER
MCF10A cells after 24 hours of 4-OHT treatment and tested
expression of 3 genes: KRT14, LAMC2 and ITGA6. We
observed an approximately 50 % reduction of relative mRNA
expression for all 3 genes upon activation of MYC-ER
(Fig. 1B). Importantly, all genes were signiﬁcantly less repressed
after activation of MYCVD-ER, suggesting the involvement of
the partner protein MIZ1 (Fig. 1B).
We then combined all signiﬁcantly repressed genes from the
4 sets shown in Figure 1A to generate a list of 339 unique line-
age-related repressed MYC target genes. This list included
genes encoding a-V and ¡6 integrins, laminin beta and gamma
chains, as well as several basal keratins, such as K5 and K14. In
order to explore their functional relationship, we performed an
enrichment analysis of Gene Ontology categories and visualized
over-represented terms in a concept overlap graph using Con-
sensusPathDB.26,27 Consistent with our previous observations,
repressed genes were involved in epithelial development, prolif-
eration and differentiation as well as several processes related to
cellular adhesion, including wound healing, migration and
extracellular matrix (ECM) organization (Fig. 1C and ref. 7).
We concluded that MYC represses a basal-like breast cancer
gene signature in a MIZ1-dependent manner and that
repressed genes are connected to key biological processes previ-
ously associated with basal/myoepithelial cells.28
Several MYC-repressed genes, including ACTA2, ITGA6,
KRT14 and SNAI2, are not only part of the breast cancer signa-
tures described above but also characteristic markers of the
normal basal cell lineage in the mammary gland.28 To further
conﬁrm that MYC suppresses lineage-speciﬁc gene expression
proﬁles associated with normal mammary epithelial subpopula-
tions, we used datasets of conserved signature genes derived
from functionally analogous mouse and human mammary epi-
thelial cells.29 These signatures are composed of genes that are
differentially expressed between puriﬁed populations of the 2
main epithelial cell types within the mammary gland: The
basal/myoepithelial compartment, which is also enriched for
mammary stem cells (MaSCs), and the luminal subset, which
can be further divided into luminal progenitors and mature
cells.30,31
We analyzed regulation of the basal or luminal gene signa-
tures in response to high levels of MYC-ER in MCF10A cells.
Whereas expression of genes characteristic for luminal cells
was not signiﬁcantly affected, expression of the basal gene sig-
nature was signiﬁcantly downregulated after induction of
MYC-ER (Fig. 1D).
Thus, we concluded that high levels of MYC lead to repres-
sion of a number of conserved genes involved in maintaining
basal cell fate and lineage commitment.
MCF10A cells can be grown in 3D acinar cultures that more
closely resemble the structural organization of the normal epi-
thelial architecture within the mammary gland.32 Chronic
MYC activation during development of acinar structures indu-
ces apoptosis (Fig. 2A).33 To test whether MYC-induced apo-
ptosis correlates with disturbed lineage-identity under these
culture conditions, we treated developing MCF10A acini with
4-OHT. In 2D monolayer culture, more than 80 % of MCF10A
cells stain positive for the basal Keratin 14 (K14), while the
remaining cells are Keratin 8 (K8, luminal) or double positive.34
We could observe similar frequencies under 3D culture condi-
tions (Fig. 2B-C). Activation of high levels of MYC disturbed
acinar morphogenesis (compare size of acini in Fig. 2B). Sur-
prisingly, we could score K8-positive acini as early as 24 h after
MYC induction and after 7 d of treatment, more than 80 % of
structures contained K8- or double positive cells (Fig. 2C). In
line with these ﬁndings, we observed a selection for decreased
expression of basal Keratin 14 and a concomitant increase in
luminal Keratin 8 expression in MCF10A cells surviving consti-
tutive overexpression of high MYC levels in regular 2D culture
(Fig. 2D). Taken together, these data suggest that high levels of
Figure 1. (see previous page) The MYC/MIZ1 complex represses conserved genes of the basal cell lineage. (A) Example plots from a GSEA C2 analysis (curated gene sets)
comparing MYC-ER- and MYCVD-ER-induced gene expression changes after 24 hours of 4-OHT treatment in MCF1A cells (100 nM). All represented gene sets are signiﬁ-
cantly repressed by MYC-ER relative to MYCVD-ER and indicate that MYC selectively represses marker genes of basal breast (cancer) cells in a MIZ1-dependent manner.
ES D Enrichment score; NES D normalized enrichment score; FDR D false discovery rate. (B) qRT-PCR validating the GSEA analysis. Expression of KRT14, LAMC2 and ITGA6
in MCF10A cells was analyzed 24 hours after 4-OHT or ctr (EtOH) treatment. Data were normalized to B2M or RPS14 and plotted relative to MYC-ER ctr. Bars represent
mean C SD from 3 independent biological replicates. Each gene is signiﬁcantly repressed after activation of MYC-ER and less repressed by MYCVD-ER. p-values were cal-
culated with Student’s t-test (: p < 0.01; : p < 0.001; : p < 0.0001). (C) Concept overlap graph of functional annotations generated with ConsensusPathDB (cpdb.
molgen.mpg.de). All core enriched genes from the GSEA sets shown in A were merged into one list and used for a Gene Ontology analysis. Selected GO-terms of signiﬁ-
cantly over-represented biological processes are visualized. Edges between nodes represent shared genes between GO-terms. Numbers in each node indicate signiﬁcance
(–log10 q-value based on FDR) of the respective process. (D) Beeswarm boxplot depicting regulation of previously identiﬁed marker genes of the basal and luminal mam-
mary epithelial lineage after activation of MYC-ER. Conserved gene signatures of basal (MaSC-enriched) and luminal (luminal progenitor and mature luminal) subpopula-
tions were retrieved from.29 P-values were determined with a Wilcoxon rank sum test.
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MYC lead to a cell fate “switch” toward the luminal mammary
epithelial lineage.
In summary, we present here evidence that high levels of
MYC repress marker genes characteristic of basal mammary
epithelial cells in a MIZ1-dependent manner. As several of
these genes have previously been suggested to be essential
determinants of basal lineage commitment and cell fate,28,29 we
propose that MIZ1-dependent repression corrupts critical sig-
nals that are required to maintain survival of this cell type. This
mechanism may play important roles in vivo, limiting the
cancerous spread of cells with potentially oncogenic levels of
MYC (Fig. 3).
Discussion
A number of observations suggest that high levels of MYC are
detrimental to epithelial cells, which is considered as a failsafe
mechanism to prevent accumulation of cancerous cells in the
body. For example, whereas both low and high MYC protein
levels induce transcription of the tumor suppressor ARF, only
high levels lead to accumulation of ARF protein by blocking
ULF-mediated ARF turnover.35 Furthermore, it has been sug-
gested that due to an invasion of low-afﬁnity sites in promoters
and enhancers, high levels of MYC can regulate additional gene
expression programs, including those involved in apoptosis.6,8
Last, complex formation with other transcriptional regulators
such as MIZ1 can modulate transcriptional responses upon
MYC overexpression.6,7 It is likely that these quantitative
changes in gene expression patterns represent essential molecu-
lar cues that allow differentiation between physiological and
oncogenic levels of MYC and, ultimately, crossing of the apo-
ptotic “threshold.”36
We demonstrated previously that association with MIZ1 and
subsequent repression of target genes of the SRF transcription
factor are required to induce apoptosis in response to onco-
genic MYC levels.7 Here, we show that MYC/MIZ1-mediated
Figure 2. High levels of MYC lead to a cell fate switch in MCF10A cells. (A) Myc activation induces apoptosis in developing acini. Representative pictures of control and 4-
OHT treated MCF10A cells after 8 d in 3D culture (7 d 4-OHT). Cleavage of Caspase-3 indicates apoptosis. E-Cadherin staining was performed to visualize acinar structure.
Nuclei are counterstained with Hoechst. Scale bar D 10 mm. (B) Myc activation induces a basal-to-luminal cell fate switch in 3D culture. Developing acini were treated
with 4-OHT (1–7 days) and analyzed for expression of Keratin 14 and 8. Representative images are shown. Scale bar D 10 mm. (C) Quantiﬁcation of B. Mean C SD of n D
3 independent experiments. 25–75 acini per group were analyzed. P-values were calculated with a Student’s t-test (: p < 0.05; : p < 0.01; : p < 0.001). (D) Immuno-
blot documenting expression of K14 (basal Keratin 14) and K8 (luminal Keratin 8) in MCF10A cells after constitutive MYC overexpression. VINCULIN was used as loading
control.
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repression targets speciﬁc cell fate determining gene modules.
In line with our previous ﬁndings, these genes are predomi-
nantly involved in biological processes such as adhesion and
cytoskeletal organization (Fig. 1C and ref. 7). One particularly
interesting conserved pathway with an important role in both
basal and stem cell-enriched subpopulations of murine and
human mammary epithelial cells is integrin signaling.29 In
addition, based on differential expression relative to other sub-
populations, extracellular matrix and cytoskeleton modules
have emerged as key operational networks in basal/myoepithe-
lial cells.28 In the same study, it was suggested that MYC is a
crucial factor for mammary cell fate decisions, in particular for
controlling the balance between basal and luminal differentia-
tion.28 Interestingly, overexpression of MYC in basal mammary
epithelial cells does not only repress basal marker genes but
also promotes a cell fate shift toward the luminal lineage
(Fig. 2B-C). It is possible that this abrupt and “unlicensed”
switch in cell identity causes apoptosis of basal epithelial cells
in vivo, due to MYC/MIZ1-mediated repression of critical,
basal-speciﬁc adhesion genes and subsequent loss of contact
with the ECM (Fig. 3, right panel). Thus, we propose that
MYC/MIZ1-dependent transcriptional repression contributes to
intrinsic tumor suppression mechanisms partly by switching
epithelial cell identity.
MYC/MIZ1-dependent transcriptional repression could also
inhibit tumorigenesis originating from adult mammary stem
cells, which are believed to be located in the basal
compartment.31
Interestingly, ectopic expression of MYC in the basal layer of
the murine epidermis causes depletion of stem cells and
increased differentiation.39,40 Furthermore, this exit from the
stem cell compartment has been linked to repression of adhe-
sion genes and the disruption of critical interactions between
stem cells and their speciﬁed microenvironment or “niche.”41,42
Most notably, repression of these genes has already been shown
to depend on association with MIZ1.43 Thus, it is tempting to
speculate that MYC/MIZ1-dependent repression of the gene
expression programs reported here could simultaneously repre-
sent an inbuilt fail-safe mechanism to prevent expansion of
mammary stem cells with oncogenic MYC. (Fig. 3, right
panel).31
Last, we also wish to point out that MYC is normally highly
expressed in luminal epithelial cells of both murine and human
mammary gland and this expression is important for luminal
progenitor proliferation and survival (Fig. 3, left panel).37,38
Levels of MYC that are supraphysiological in the basal cells
studied here might therefore be tolerated in luminal cells. It is
tempting to speculate hat rare premalignant cells could survive
the MYC-induced cell identity switch and these cancerous cells
with new luminal identity will eventually beneﬁt from MYC/
MIZ1 pro-survival functions. From this angle, the MYC-
induced cell fate switch could also be considered as a tumor
survival mechanism. To summarize, it is conceivable that
MYC/MIZ1-dependent modulation of mammary epithelial
identity has a paramount inﬂuence on mammary tumor devel-
opment, being able to either suppress or promote the tumori-
genesis depending on the context and the stage of the pre-
malignant or malignant lesion.
Despite a variety of tumor-suppressive mechanisms, deregu-
lated MYC expression is frequently observed in human breast
cancer and most commonly associated with the basal/triple-
negative subtype.44,45 As this type of cancer has been proposed
to originate in luminal progenitor cells, this could reﬂect a
“memory” of the physiological expression pattern of MYC in
this compartment.46 Alternatively, as the majority of these
tumors have lost expression of the p53 tumor suppressor,
MYC/MIZ1-dependent gene repression might be tolerated
because apoptosis can be escaped.7 Further studies will
Figure 3. Model summarizing possible consequences of MYC expression/deregulation in the mammary gland. Left panel: During normal development, endogenous MYC
is required to suppress basal gene expression programs (in a complex with MIZ1), leading to a conﬁnement of MYC expression to the luminal compartment of the mam-
mary gland during tissue homeostasis. Right panel: Deregulated MYC expression in either mammary stem cells (MaSC) or basal cells leads to MIZ1-dependent repression
of adhesion genes and causes disruption of critical cell – niche or cell - ECM interactions and consequently, promotes apoptosis. Therefore, the MYC/MIZ1-induced cell
identity switch could act as a critical fail-safe mechanism to prevent tumorigenesis within the basal/stem cell compartment.
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determine whether the potential MYC-induced cell fate switch
observed here bears similarities to recent discoveries of onco-
gene-induced cell fate conversions in lineage restricted subpo-
pulations and whether it contributes to tumor heterogeneity in
human breast cancer.47,48
Materials and methods
Tissue culture and lentiviral transduction
2D and 3D organotypic culture of MCF10A and MCF10A
MycERtm cells was performed as previously described.7,33 Stable
overexpression of MYC or MYC-ER fusion proteins was
achieved by transduction with lentiviral pRRL-SFFV vectors
and packaging plasmids psPAX2 and pMD2.G (Didier Trono)
in the presence of 8 mg/ml protamine sulfate.
Cells were either treated with 100 nM 4-OHT to induce
expression of MYC-ER, or ethanol as solvent control.
Gene expression, GSEA and Gene Ontology analysis
Total RNA was extracted with peqGOLD TriFast Reagent
(PEQLAB). First-strand cDNA synthesis was performed with
M-MLV Reverse Transcriptase (Invitrogen) and random hex-
amer primers (Roche). Gene expression was analyzed by qRT-
PCR on an Agilent MX3000P platform in technical triplicates
using ABsolute SYBR Green Mix (Thermo Scientiﬁc) and the
following primers (50¡30): ccattgaggacctgaggaac and caatctgca-
gaaggacattgg (KRT14); ctcagcccaacgactagacc and tcacctgttgattcc-
caaga (LAMC2); tttgaagatgggccttatgaa and
ccctgagtccaaagaaaaacc (ITGA6). Data were quantiﬁed with the
comparative CT method using B2M (50gtgctcgcgctactctctc30 and
50gtcaacttcaatgtcggat30) or RPS14 (50ggcagaccgagatgaatcctca30
and 50caggtccaggggtcttggtcc30) as reference for normalization.
Results from 3 independent biological experiments were com-
bined to calculate relative expression and determine signiﬁ-
cance. The microarray analysis is described in ref. Seven.
To analyze differentially repressed gene sets between MYC-
ER and MYCVD-ER, M-values from the microarray analysis
were used for a gene set enrichment analysis (GSEA) of curated
gene sets (“C2”). The two different phenotypes were compared
with n D 1000 permutations and permutation type “gene_set.”
To analyze which functional annotation categories are over-
represented among differentially repressed genes, we used all
core enriched genes (signiﬁcantly repressed by MYC-ER rela-
tive to MYCVD-ER) from the 4 curated gene sets shown in
Fig. 1A. The resulting list of 339 unique genes was analyzed
with the web interface of ConsensusPathDB (http://consensus
pathdb.org) and selected Gene Ontology categories were visual-
ized in a concept overlap graph.27
Analysis of conserved lineage signature genes
To determine the regulation of previously identiﬁed conserved
lineage signature genes by MYC, we used Supplementary
Tables 1, 2 and 3 published by Lim et al.29 Upregulated genes
in MaSC-enriched (“Basal”), or luminal progenitor and mature
luminal subsets (“Luminal”) were merged with signiﬁcantly
regulated genes after MYC-ER induction in MCF10A cells (p <
0.05). The overlap between both lists (153 basal (31 %) and 67
(38 %) luminal genes, respectively) was displayed in a bees-
warm boxplot using the R environment. Signiﬁcance was deter-
mined with a 2-sided Wilcoxon rank sum test.
Immunoﬂuorescence (IF) staining of 3D MCF10A cultures
Acinar structures were immunostained according to established
protocols.49 Brieﬂy, acini were ﬁxed with 2 % PFA for 15 min
and permeabilized with 0.25 % Triton X-100/PBS for 10 min
and blocked with 10 % goat serum/PBS for 1 h. Primary anti-
bodies were diluted in IF-buffer (0.1 % BSA/0.2 % Triton X-
100/0.05 % Tween-20 in PBS) and 3D cultures were stained
overnight. Following washes (3£15 min with IF-buffer), struc-
tures were incubated with secondary antibodies and washed
again. Nuclei were counterstained with Hoechst 33258 (Life
Technologies) and mounted with Immu-Mount reagent (Fisher
Scientiﬁc). Imaging was performed on a Leica TCS CARS SP8
confocal microscope.
Antibodies
Anti-cleaved Caspase-3 (1:300, Asp175, #9661, Cell Signaling),
anti-E-Cadherin (1:500, 36/E-Cadherin, BD Biosciences), anti-
Keratin 8 (1:300, 1E8, Biolegend), anti-Keratin 14 (1:300,
Poly19053, Biolegend) and appropriate Alexa Fluor® conjugated
secondary antibodies (Life Technologies) were used for 3D-IF
stainings. Anti-Keratin 8 (M20, Acris Antibodies GmbH), anti-
Keratin 14 (LL002, abcam) and anti-Vinculin (hVIN-1, Sigma)
were used for immunoblot.
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